Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Lisa Zimmer, Elisabeth Livingstone, Angela M. Krackhardt, Erwin Schultz, Daniela Göppner, Chalid Assaf, D. Trebing, Kai Stelter, Christine Windemuth-Kieselbach, Selma Ugurel, Dirk Schadendorf
Topics & Concepts
MedicineTolerabilityPembrolizumabMelanomaInternal medicineGastroenterologyPharmacologyPlaceboAdverse effectOncologyImmunotherapyCancerCancer researchPathologyAlternative medicineMelanoma and MAPK PathwaysCutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers